Am 80 (tamibarotene)

Subscribe to Selected New Research on Am 80

34 relevant articles (5 outcomes, 5 trials/studies) found for this Bio-Agent

Description: has retinoid-binding activity

Also Known As:

tamibarotene; 4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid; AM-80; Am80; Benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Cyclic Hydrocarbons: 3

Aromatic Hydrocarbons: 121

Aromatic Polycyclic Hydrocarbons: 617

Naphthalenes: 10

Tetrahydronaphthalenes: 1

Polycyclic Compounds: 59

Aromatic Polycyclic Hydrocarbons: 617

Naphthalenes: 10

Tetrahydronaphthalenes: 1

Am 80: 34

Experts

1.	Niwa, S: 3 articles (11/2000 - 05/2000)
2.	Shudo, K: 3 articles (11/2000 - 05/2000)
3.	Nagai, H: 3 articles (11/2000 - 05/2000)
4.	Wang, T: 3 articles (11/2000 - 05/2000)
5.	Kagechika, Hiroyuki: 2 articles (05/2006 - 11/2004)
6.	Shudo, Koichi: 2 articles (05/2006 - 11/2004)
7.	Takeuchi, Makoto: 2 articles (03/2006 - 11/2003)
8.	Bouda, K: 2 articles (11/2000 - 09/2000)
9.	Homma, T: 2 articles (11/2000 - 09/2000)
10.	Matsuura, S: 2 articles (11/2000 - 09/2000)

Related Diseases

1.	Acute Promyelocytic Leukemia 07/01/2009 - "We used our micro-reversed fragment-based drug design hypothesis and multi-template hypothesis to extract the tetrahydrotetramethylnaphthalene (TMN) skeleton from tamibarotene, a useful medicament for the treatment of acute promyelocytic leukemia (APL). " 08/01/2007 - "Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. " 03/01/2006 - "[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia]" 05/15/1996 - "Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80." 12/01/2000 - "A new synthetic retinoid, Am80, is effective in treating acute promyelocytic leukemia relapsed from all-trans-retinoic acid-induced complete remission (CR). " Order ALL the reference details at left...
2.	Leukemia 08/01/2007 - "Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. " 10/01/1995 - "4-[5H-2,3-(2,5-Dimethyl-2,5-hexano)-5-methyldibenzo[b, e]diazepin-11-yl]benzoic acid (4) enhanced the differentiation-inducing activity of retinoic acid (1) and of a synthetic retinoid Am80 (2) toward human promyelocytic leukemia cells HL-60, although 4 alone did not induce differentiation. " 10/01/1989 - "N-Methylation of two retinoidal amide compounds, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benz oic acid (3, Am80) and 4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalenyl)carbonyl]amino]benzoic acid (5, Am580), resulted in the disappearance of their potent differentiation-inducing activity on human promyelocytic leukemia cell line HL-60. " 10/01/1990 - "The retinobenzoic acids Am80, Am580 and Ch55 are synthetic stable analogs of retinoic acid (RA), and show very strong differentiation-inducing activity in human myelogeneous leukemia cell line HL-60. " 04/01/1988 - "The uptake of all-trans-retinoic acid (RA) and two new retinoids [4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenylcarbamoyl )benzoic acid (Am80) and (E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxo-1-propenyl]benzoic acid (Ch55)] by HL-60 human promyelocytic leukemia cells was investigated. " Order ALL the reference details at left...
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/01/2009 - "Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis." 11/01/2000 - "Effect of selective IL-6 inhibitor Am-80 on experimental autoimmune encephalomyelitis in DA rats." 09/01/2000 - "The effect of Am-80, one of retinoids derivatives on experimental allergic encephalomyelitis in rats." 06/01/2009 - "Here, we investigated the effects of AM80, a synthetic retinoid with enhanced biological properties to all-trans retinoic acid, on Th17 differentiation and function and evaluated its therapeutic potential in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. " Order ALL the reference details at left...
4.	Psoriasis (Pustulosis Palmaris et Plantaris) 06/01/2006 - "Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL. " Order ALL the reference details at left...
5.	Neoplasms (Cancer) 11/01/2008 - "Furthermore, severe combined immunodeficient mice with tumors induced by subcutaneous inoculation of HTLV-I-infected T cells, responded to Am80 treatment with partial regression of tumors and no side-effects. " 08/01/2007 - "We studied the tumor cell suppressive effects of Am-80, with respect to cytotoxicity and growth inhibition using eight myeloid and lymphoid malignant cells in culture (HL-60, HL-60R, K-562, Kasumi-1, MEG01, Raji, U266B1, and U937). " 01/01/2003 - "In this study, we applied the class prediction algorithm, which was used in the molecular phenotyping of tumors, for the classification of synthetic retinoids (Am80 and Tp80) and retinoid synergists (HX630, TZ335, and PA024) as all-trans retinoic acid-like, 9-cis retinoic acid-like, and control-like classes. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tretinoin (Retinoic Acid)
2.	Am 80 (tamibarotene)
3.	Retinoids
4.	HX 630
5.	Amyloid (Amyloid Fibrils)
6.	Benzoic Acid (Ucephan)
7.	Interleukin-6 (Interleukin 6)
8.	Collagen Type II (Type II Collagen)
9.	Interleukin-10 (Interleukin 10)
10.	Cytokines

Related Therapies and Procedures

1.	Oral Administration
2.	Therapeutics

Best Treatments:
Research Summary Report
on Acute Promyelocytic Leukemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 388 Outcomes
Top 200 Key Drugs and Biologics
Top 37 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>